AbbVie has acquired Apogee Therapeutics for $10.9 billion to bolster its immunology franchise with Apogee's lead drug, zumilokibart, which shows promise in treating autoimmune conditions. Separately, the AI startup Cadence has raised $100 million at a $1.2 billion valuation, led by Spark Capital. Cadence utilizes AI agents to monitor patients with chronic diseases, aiming to improve health outcomes and reduce healthcare costs, reportedly saving Medicare over $2 million weekly. AI
IMPACT AI's role in chronic disease management is validated, potentially reducing healthcare costs and improving patient outcomes.
RANK_REASON The cluster contains a major acquisition by a large pharmaceutical company and a significant funding round for an AI-focused health tech startup. [lever_c_demoted from significant: ic=1 ai=0.7]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
